← Back to Patent Explorer
US4061735A Expired / Lapsed US ⏱️ 0.0 years remaining

Haptoglobin in aqueous solution and process for preparing the same

Assignee: Tanabe Pharma Corp
•
Filing: 1976-04-15
•
Granted: 1977-12-06
•
Expires: 1996-04-15
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An aqueous solution of haptoglobin is obtained by subjecting an aqueous solution of alpha and beta -globulin fractions of human blood plasma to further fractionation by use of ammonium sulfate, collecting fractions precipitated at a concentration between 30% and 40% saturation of ammonium sulfate, contacting a reconstituted aqueous solution of the collected fractions with an anion exchanger to adsorb haptoglobin on said anion exchanger, selectively eluting the haptoglobin from the anion exchanger, and then concentrating the resulting aqueous eluate solution. The aqueous solution of haptoglobin is subjected to heat treatment in the presence of a selected stabilizing agent for inactivating hepatitis B virus at an optional step of the process.

Inventors

  • 👤 Satoshi Funakoshi
  • 👤 Takao Omura
  • 👤 Takeshi Ohshiro

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-25 19:58
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; A; A61; A61K; A61K38/00; A61L; A61L2/00; A61L2/02; A61L2/04; A61L2103/00; A61L2103/05; A61L2103/09

Claims Analysis

Total Claims: 13
Claim 1
Independent Claim 69 words
An aqueous solution of human serum haptoglobin suitable for the therapy of renal disorders derived from massive hemolysis which has less than 10% in hypotensive activity, is highly stable during storage and which has been subjected to heat treatment in the presence of at least one stabilizing agent selected from the group consisting of neutral amino acids, monosaccharides, disaccharides and soluble sugar alcohols, for inactivating hepatitis B virus (HB-Ag).
Claim 2
Dependent Claim 69 words
An aqueous solution of human serum haptoglobin suitable for the therapy of renal disorders derived from massive hemolysis which has less than 10% in hypotensive activity, is highly stable during storage and which has been subjected to heat treatment in the presence of at least one stabilizing agent selected from the group consisting of neutral amino acids, monosaccharides, disaccharides and soluble sugar alcohols, for inactivating hepatitis B virus (HB-Ag).
Claim 3
Dependent Claim 24 words
The aqueous solution of claim 1, wherein the concentration of haptoglobin is 5 to 155% by weight based on the volume of the solution.
Claim 4
Dependent Claim 15 words
The aqueous solution of claim 1, wherein the purity of haptoglobin is at least 65%.
Claim 5
Dependent Claim 15 words
The aqueous solution of claim 1, wherein the purity of haptoglobin is 65 to 91%.
Claim 6
Dependent Claim 23 words
The aqueous solution of claim 1, wherein the stabilizing agent is a neutral amino acid and is glycine, alanine, valine, leucine or isoleucine.
Claim 7
Dependent Claim 20 words
The squeous solution of claim 1, wherein the stabilizing agent is a monosaccharide and is glucose, mannose, galactose or fructose.
Claim 8
Dependent Claim 19 words
The aqueous solution of claim 1, wherein the stabilizing agent is a disaccharide and is sucrose, maltose or lactose.
Claim 9
Dependent Claim 21 words
The aqueous solution of claim 1, wherein the stabilizing agent is a soluble sugar alcohol and is mannitol, sorbitol or xylitol.
Claim 10
Dependent Claim 20 words
The aqueous solution of claim 1, wherein the heat treatment had been carried out at 60° C for 10 hours.
Claim 11
Dependent Claim 15 words
The aqueous solution of claim 1, wherein the stabilizing agent had been removed by dialysis.
Claim 12
Dependent Claim 27 words
The aqueous solution of claim 1, wherein the amount of the stabilizing agent added is at least 5% by weight based on the volume of the solution.
Claim 13
Dependent Claim 27 words
The aqueous solution of claim 1, wherein the amount of the stabilizing agent added is 15 to 20% by weight based on the volume of the solution.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-12-05 1981-06-06 1981-12-06 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-12-05 1985-06-06 1985-12-06 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-12-05 1989-06-06 1989-12-06 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag